[Ataxia in rolling mouse Nagoya and the norepinephrine system--a psychopharmacological study].
Rolling mouse Nagoya (RMN), an ataxia mutant mouse, is adequate to checking up the efficacy of drugs on the ataxic movement disorders. The effects of some drugs on the ataxia of RMN were investigated by open field study. The drugs administered to RMN were as follows: TRH, FLA-63, DL-threo-DOPS, phenoxybenzamine and propranolol. Ataxic gait of RMN were remarkably improved by TRH, but remained unchanged by other drugs. The pretreatments with FLA-63, DOPS and phenoxybenzamine were not influenced to the antiataxic effects of TRH, while the pretreatment with propranolol increased the antiataxic effect of TRH in RMN. These results suggest that mechanism of the improvement of ataxic gait by TRH may not be sufficiently explained through only changing norepinephrine metabolism.
D000818:Animals; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism*; D002524:Cerebellar Ataxia / Q000188:drug therapy / Q000378:metabolism*; D004195:Disease Models, Animal; D015103:Droxidopa / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D009638:Norepinephrine / Q000378:metabolism*; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use
D010643:Phenoxybenzamine; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; D013973:Thyrotropin-Releasing Hormone; D011433:Propranolol; D015103:Droxidopa; D009638:Norepinephrine